GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurisco Pharmaceutical Co Ltd (SHSE:605116) » Definitions » Debt-to-Revenue

Aurisco Pharmaceutical Co (SHSE:605116) Debt-to-Revenue : 0.61 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Aurisco Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aurisco Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥47 Mil. Aurisco Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥926 Mil. Aurisco Pharmaceutical Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥1,608 Mil. Aurisco Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.61.


Aurisco Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Aurisco Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurisco Pharmaceutical Co Debt-to-Revenue Chart

Aurisco Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.01 0.02 0.05 0.09 0.64

Aurisco Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.61 0.61 0.61

Competitive Comparison of Aurisco Pharmaceutical Co's Debt-to-Revenue

For the Biotechnology subindustry, Aurisco Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurisco Pharmaceutical Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aurisco Pharmaceutical Co's Debt-to-Revenue falls into.


;
;

Aurisco Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aurisco Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(25.661 + 922.191) / 1475.741
=0.64

Aurisco Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(46.741 + 926.338) / 1607.98
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Aurisco Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aurisco Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurisco Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Badu Industrial Park, Tiantai County, Zhejiang Province, Taizhou, CHN, 317200
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
Executives
Qiu Pei Jing Director
Zhao Zhen Ping senior management
Zhang Li Qin senior management

Aurisco Pharmaceutical Co Headlines

No Headlines